Genesee Capital Advisors LLC Grows Stock Holdings in Cencora, Inc. $COR

Genesee Capital Advisors LLC boosted its position in Cencora, Inc. (NYSE:COR) by 1.8% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 6,072 shares of the company’s stock after acquiring an additional 110 shares during the period. Genesee Capital Advisors LLC’s holdings in Cencora were worth $1,821,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Voleon Capital Management LP purchased a new stake in Cencora in the 1st quarter worth approximately $3,111,000. Exchange Traded Concepts LLC grew its stake in Cencora by 4.5% in the 1st quarter. Exchange Traded Concepts LLC now owns 1,104 shares of the company’s stock worth $307,000 after acquiring an additional 48 shares during the period. Focus Partners Wealth grew its stake in Cencora by 25.8% in the 1st quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock worth $1,589,000 after acquiring an additional 1,171 shares during the period. Fiduciary Alliance LLC purchased a new stake in Cencora in the 2nd quarter worth approximately $262,000. Finally, Martin Capital Partners LLC boosted its holdings in shares of Cencora by 205.2% in the 2nd quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock valued at $1,135,000 after purchasing an additional 2,544 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $290.00, for a total value of $1,478,130.00. Following the transaction, the chief executive officer owned 39,274 shares in the company, valued at $11,389,460. The trade was a 11.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 55,993 shares of company stock worth $16,292,923 in the last quarter. 10.80% of the stock is currently owned by company insiders.

Cencora Stock Performance

NYSE:COR opened at $318.01 on Monday. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. The firm has a market capitalization of $61.66 billion, a price-to-earnings ratio of 32.72, a PEG ratio of 1.49 and a beta of 0.63. The firm’s fifty day simple moving average is $296.99 and its 200 day simple moving average is $291.87. Cencora, Inc. has a twelve month low of $221.95 and a twelve month high of $319.68.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.21. The business had revenue of $80.66 billion for the quarter, compared to analyst estimates of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.34 EPS. As a group, equities research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, August 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is presently 22.63%.

Analyst Ratings Changes

A number of equities analysts have weighed in on COR shares. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a report on Saturday. Jefferies Financial Group lifted their price target on shares of Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a report on Monday, June 30th. Evercore ISI set a $340.00 price target on shares of Cencora in a report on Wednesday. Wells Fargo & Company lifted their price target on shares of Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Cencora in a report on Wednesday, October 8th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $320.00.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.